Contraceptive vaginal ring

Clin Obstet Gynecol. 2007 Dec;50(4):878-85. doi: 10.1097/GRF.0b013e318159c07e.

Abstract

The vaginal contraceptive ring is comprised of ethinyl vinyl acetate that releases ethinyl estradiol and the third-generation progestin, etonorgestrel. It was approved by the Food and Drug Administration in 2001. The vaginal contraceptive ring is highly efficacious with a Pearl Index of 1.18 and an efficacy of 99.1%. Effectiveness is similar with actual use.

Publication types

  • Review

MeSH terms

  • Contraceptive Agents, Female / pharmacokinetics*
  • Contraceptive Agents, Female / pharmacology*
  • Contraceptive Devices, Female / adverse effects*
  • Contraceptive Devices, Female / standards*
  • Contraceptive Devices, Female / statistics & numerical data
  • Desogestrel / pharmacokinetics
  • Desogestrel / pharmacology
  • Drug Combinations
  • Ethinyl Estradiol / pharmacokinetics
  • Ethinyl Estradiol / pharmacology
  • Female
  • Humans
  • Ovulation / drug effects*
  • Patient Compliance
  • Patient Satisfaction
  • Treatment Outcome

Substances

  • Contraceptive Agents, Female
  • Drug Combinations
  • etonogestrel
  • Ethinyl Estradiol
  • Desogestrel